Episode 40: From Discovery to Treatment with Dr Stuart Lipton

Dr. Stuart Lipton, the neuroscientist and clinician who discovered MEF2C, joins MEF2Cast to discuss the science behind MEF2C haploinsufficiency syndrome and the ongoing effort to develop potential treatments.

Dr. Lipton shares the story of how MEF2C was discovered almost by accident while he was cloning another gene, and how experiments in mice eventually revealed its connection to autism-like behaviors. He explains what MEF2C does throughout brain development, why the amount of MEF2C activity matters, and how changes in the gene can contribute to the wide range of features associated with MEF2C haploinsufficiency syndrome.

The conversation then moves into current research and therapy development, including several approaches being investigated to address the underlying biology of the condition. Dr. Lipton explains how researchers are using mouse models, patient-derived cells, and brain organoids to better understand MEF2C and evaluate potential treatments.

Subjects covered include:

• How MEF2C was discovered and the surprising findings that connected it to autism

• The role of MEF2C in neuron formation, synapse development, and synaptic pruning

• Why MEF2C dosage matters and how its role changes across the lifespan

• The features and characteristics associated with MEF2C haploinsufficiency syndrome

• How MEF2C fits into the broader network of genes associated with autism

• Excitatory-inhibitory imbalance and the role of excess glutamate signaling

• The development of nitrosynapsin as a potential therapeutic approach

• Using small molecules to increase activity from the remaining healthy MEF2C copy

• RNA-targeted and gene-level approaches to treatment

• Why CRISPR-style gene correction is not yet ready for clinical use

• Using patient-derived cells, stem cells, and brain organoids to model MEF2C

• Studying seizures and treatment responses in organoids

• Preclinical findings involving nitrosynapsin and social behavior

• Biomarkers and the challenge of measuring treatment response

• Natural history studies and designing clinical trials for rare diseases

• FDA requirements and the path from laboratory research to human trials

• The challenges of funding and developing treatments for neurological conditions

• Advice and hope for families living with an MEF2C haploinsufficiency syndrome diagnosis

Dr. Lipton also discusses the challenges that come with developing treatments for conditions affecting the brain, while offering a hopeful perspective on the progress being made. From understanding the biology of MEF2C to testing potential therapies and preparing for future clinical trials, this conversation provides an inside look at where MEF2C research stands and where it may be headed.

MEF2Cast is dedicated to sharing information, research, personal experiences, and conversations surrounding MEF2C haploinsufficiency syndrome.

MEF2Cast is for educational and informational purposes and is not a substitute for medical advice from a qualified healthcare professional.